Palbociclib + Letrozole or Fulvestrant

DRUG2 trials

Sponsors

Georgetown University, SOLTI Breast Cancer Research Group

Conditions

Hormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast Cancer

Phase 2

Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer

CompletedNCT02692755

Georgetown UniversityHormone Receptor Positive HER-2 Negative Breast Cancer

Start: 2016-09-30End: 2021-03-23Updated: 2021-09-28

Phase 3

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

TerminatedNCT05207709

SOLTI Breast Cancer Research GroupMetastatic Breast Cancer

Start: 2022-03-28End: 2026-03-26Updated: 2026-06-25

Related Papers

Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2-metastatic breast cancer patients: a multicenter study (YOUNGBC-28).

2024-12-171 citations

CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial

The Oncologist2024-01-0412 citations

Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.

Journal of Clinical Oncology2023-06-014 citations

Abstract P1-13-16: Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)

Cancer Research2023-03-01

Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer

Cancer2021-06-2218 citations

PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer

Contemporary Clinical Trials Communications2018-05-0711 citations